1. Home
  2. Research
  3. Research Groups
  4. Molecular Pathology of Cancer Group

Molecular Pathology of Cancer Group

Search for publications

Only original articles, editorials, guidelines.

  • Konstantinopoulos PA, Kim JW, Freyer G, Lee JY, Gaba L, Grisham RN, Colombo N, Wu X, Sehouli J, Cruz F, Cibula D, Monk BJ, Nyvang GB, Friedlander M, Lorusso D, Van Nieuwenhuysen E, Malik R, Glasspool R, Marth C, Leary A, Cortés-Salgado A, Zamagni C, Marmé F, Sufliarsky J, Hinson P, Zuradelli M, Wang C, Su F, Paule I, Miller M, Matulonis UA, González-Martín A.

    Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation.

    JOURNAL OF CLINICAL ONCOLOGY . 43(26): 2908-2917.

    [doi:10.1200/JCO-25-00225]

  • Aguzzi C, De Summa S, Molina-Cerrillo J, Alonso-Gordoa T, Nabissi M, Rizzo M, Zeppellini A, Sunela K, Sorgentoni G, Ortega C, Massari F, Marques Monteiro FS, Battelli N, Porta C, Santoni G, Santoni M.

    mRNA expression, tumor heterogeneity, and response to therapy in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1a).

    Biochemistry and Biophysics Reports . 43: 102162-102162.

    [doi:10.1016/j.bbrep.2025.102162]

  • López-Miranda E, Pérez-García JM, Gión M, Ribelles N, Cortez-Castedo P, Alonso-Romero JL, García MM, González-Santiago S, Bermejo B, Morales S, Carañana V, Garrigós L, Fernández-Pinto M, García-Vicente S, Garcia-Sanz A, Mena-Molina A, Boix O, Alcalá-López D, Llombart-Cussac A, Cortés J.

    Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial.

    BREAST CANCER RESEARCH . 27(1): 141-141.

    [doi:10.1186/s13058-025-02089-4]

  • Bourlon MT, Galli L, Grande E, Park SH, Melichar B, Schieber TJ, Juan-Fita MJ, Ürün Y, Molina-Cerrillo J, Alonso-Gordoa T, De Giorgi U, Kucharz J, Pérez Calabuig E, Conteduca V, Taha T, Rescigno P, Abu-Sini H, Spinelli GP, Manneh Kopp R, Salfi A, Bhuva D, Valdez-Sandoval P, Mendez-Bribiesca S, Fiala O, Buti S, Marques Monteiro FS, Bamias A, Ghosn M, Massari F, Ansari J, Santoni M.

    Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study.

    Frontiers in Oncology . 15: 1605282-1605282.

    [doi:10.3389/fonc.2025.1605282]

  • Zapatero A, Alonso-Gordoa T, Rodríguez Antolín A, Couñago F, Sanmamed N, Domínguez Esteban M, López Valcárcel M, Manneh R, Borque-Fernando Á, Sala González N, Maroto P.

    Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach.

    Oncology Reviews . 19: 1599292-1599292.

    [doi:10.3389/or.2025.1599292]

  • Manneh R, Molina-Cerrillo J, de Velasco G, Ibatá L, Martínez S, Ruiz-Granados Á, Alonso-Gordoa T.

    PARP Inhibitors for Metastatic CRPC: More Answers than Questions, a Systematic Review and Meta-Analysis.

    PHARMACEUTICALS . 18(7): .

    [doi:10.3390/ph18071015]

  • Pérez-García JM, Gion M, Ruiz-Borrego M, Blancas I, López-Miranda E, Blanch S, Recalde S, Rendo CR, González X, Ancizar N, Morales S, Cortez P, Piwowarska Z, Shimizu E, Guerrero JA, Sampayo-Cordero M, Martínez-Bueno A, Cortés J, Llombart-Cussac A.

    Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial.

    Eclinicalmedicine . 85: 103309-103309.

    [doi:10.1016/j.eclinm.2025.103309]

  • Loibl S, Martin M, Bonnefoi H, Untch M, Kim SB, Bear HD, García-Sáenz JA, Melé Olivé M, Mc Carthy N, Gelmon K, Kelly CM, Im SA, Reimer T, Martinez-Janez M, Zhang Z, Toi M, Provencher L, Rugo HS, Gnant M, Makris A, Antón Torres A, Hirmas N, Holtschmidt J, Nekljudova V, Marmé F.

    Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy.

    Annals of oncology : official journal of the European Society for Medical Oncology . 36(7): 832-837.

    [doi:10.1016/j.annonc.2025.03.010]

  • Niedra H, Rogoza O, Saksis R, Peculis R, Halilova A, Gerina A, Vilisova S, Senterjakova N, Pukitis A, Ruz-Caracuel I, Earl J, Kolnikova G, Dubovan P, Tomas M, Makovicky P, Urbanova M, Smolkova B, Koniaris E, Aggelioudaki I, Kataki A, Rovite V.

    Transcriptomic profiling of pancreatic neuroendocrine tumors: dysregulation of WNT, MAPK, PI3K, neddylation pathways and potential non-invasive biomarkers.

    Plos One . 20(6): .

    [doi:10.1371/journal.pone.0325672]

  • Porta C, Massari F, Taha T, Grande E, Bourlon MT, Kanesvaran R, Basso U, Molina-Cerrillo J, Alonso-Gordoa T, Myint ZW, Fornarini G, Buttner T, Park SH, Ürün Y, De Giorgi U, Pichler R, Rescigno P, Buchler T, Studentova H, Melichar B, Ansari J, Mollica V, Kucharz J, Rizzo M, Rizzo A, Kopp RM, Buti S, Monteiro FSM, Soares A, Bamias A, Santoni M.

    Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study.

    CANCER IMMUNOLOGY IMMUNOTHERAPY . 74(7): 196-196.

    [doi:10.1007/s00262-025-04019-x]

  • Alonso-Gordoa T, Anguera G, Domínguez-Esteban M, Reig Ò, Martínez-Barros H, Molina-Cerrillo J, Cruz P, Maroto P.

    Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies.

    CANCER TREATMENT REVIEWS . 136: 102925-102925.

    [doi:10.1016/j.ctrv.2025.102925]

  • Herranz-Montoya I, Angulo-Aguado M, Perna C, Zagorac S, García-Jimeno L, Park S, Djouder N.

    p53 protein degradation redefines the initiation mechanisms and drives transitional mutations in colorectal cancer.

    NATURE COMMUNICATIONS . 16(1): 3934-3934.

    [doi:10.1038/s41467-025-59282-4]

  • Capdevila J, Pubul V, Anido U, Walter T, Molina-Cerrillo J, Alonso-Gordoa T, Garcia-Carbonero R, San-Roman-Gil M, Llana B, Jimenez-Fonseca P, Benavent Viñuales M, Ansquer C, Baudin E, Lepage C, Del Olmo-García M, Ruffinelli JC, Beron A, Haissaguerre M, Deshayes E, Taïeb D, Baldari S, Sansovini M, Cingarlini S, Filice A, Panzuto F, Álvarez-Álvarez R, Lousberg L, Aboubakar Nana F, Hernando J, García-Álvarez A, García-Burillo A, Villacampa G, Vandamme T, Fazio N, Durand A.

    A Randomized clinical trial evaluating the impact on survival and quality of life of (177)Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).

    Bmc Cancer . 25(1): 613-613.

    [doi:10.1186/s12885-025-13941-3]

  • Borque-Fernando Á, Alonso-Gordoa T, Juan-Fita MJ, Lopez Campos F, Pérez-Fentes DA, Vilaseca A, Agut CM, Usán P, Rey PM.

    Beyond the status quo: when disease volume and metastatic timing are not enough to personalize treatment in mHSPC.

    FUTURE ONCOLOGY . 21(8): 991-1003.

    [doi:10.1080/14796694.2025.2468569]

  • Fernández-Abad M, Caniego-Casas T, Carretero-Barrio I, Calderay-Domínguez M, Saavedra C, Hardisson D, Palacios J, Pérez-Mies B.

    Ipsilateral Breast Carcinoma Recurrence: True Recurrence or New Primary? A Clinicopathologic and Molecular Study.

    AMERICAN JOURNAL OF SURGICAL PATHOLOGY . 49(3): 294-302.

    [doi:10.1097/PAS.0000000000002351]

  • Cortés-Salgado A, Moreno-Moreno E, Carretero-Barrio I, Caniego-Casas T, Cristóbal E, Del Campo-Albendea L, Guerra E, Alía V, de Aguado PP, Corraliza V, Palacios J, Pérez-Mies B.

    HER2 expression in a molecularly defined cohort of endometrial cancer patients: The SPECTRUM study.

    GYNECOLOGIC ONCOLOGY . 194: 33-40.

    [doi:10.1016/j.ygyno.2025.02.005]

  • Tolosa P, Pascual T, Martínez-Saez O, Hernando C, Servitja S, Fernández Abad M, Brasó-Maristany F, Sanfeliu E, Benitez Fuentes JD, Lema L, Ruano Y, García-Fructuoso I, Parrilla L, Rodríguez A, Roncero AM, Cobos MÁ, Sánchez-Bayona R, Alva M, Madariaga A, Villacampa G, Canes J, Salvador F, Sánchez-Belmonte A, Malumbres M, Prat A, Ciruelos E.

    Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT study.

    EUROPEAN JOURNAL OF CANCER . 217: 115219-115219.

    [doi:10.1016/j.ejca.2024.115219]

  • Oaknin A, Monk BJ, de Melo AC, Kim HS, Kim YM, Lisyanskaya AS, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin E, Takahashi S, Ramone D, Mackowiak-Matejczyk B, Polastro L, Alia EMG, Colombo N, Makarova Y, Goh JC, Hasegawa K, Mora P, Pikiel J, Srivastav R, Rischin D, Rubio MJ, Perez J, Yoo SY, Gao B, Jamil S, Seebach F, Lowy I, Mathias M, Fury MG, Tewari KS.

    Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial.

    EUROPEAN JOURNAL OF CANCER . 216: 115146-115146.

    [doi:10.1016/j.ejca.2024.115146]